News

Forest Laboratories (Forest) has presented new data from a complete analysis of FOCUS 1 and FOCUS 2, two global multicenter phase III studies of ceftaroline for the treatment

Theravance and Astellas have reported that the FDA has approved Vibativ (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI). Vibativ is

The FDA has cleared a test that can help detect ovarian cancer in a pelvic mass that is already known to require surgery. The test, known as OVA1,

Signum Biosciences has been awarded a $1.6m Small Business Innovation Research (SBIR) phase II grant by the National Institute of Allergy and Infection Diseases (NIAID), to continue the

The FDA has approved GenSpera’s Investigational New Drug (IND) application to begin a phase I study with its target activated pro-drug, G-202, for the treatment of cancer. G-202

New data from a study conduct by Eli Lilly showed that patients with chronic low back pain on Cymbalta (duloxetine HCl) has maintained reductions in pain for 41

Delcath Systems has reported that the Data and Safety Monitoring Board (DSMB) has reviewed clinical data on 77 patients enrolled in its pivotal phase III clinical trial. DSMB

Germany-based Merck has reported the results of the complete 40-week IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study. Reportedly, the data showed a 69% reduction in the

Sanofi-aventis and Regeneron Pharmaceuticals have discontinued the phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine, for the first-line treatment of metastatic pancreatic